Anosmia and dysgeusia are two common neurological manifestations seen in COVID-19 patients, and these symptoms might appear is over 10% of cases prior to other symptoms. Pneumonia, followed by ARDS, is the most common complication faced by COVID-19 patients. Patients with overactive expression of CXCL10, an inflammatory chemokine, is correlated with patients having a more serious reaction, and in mice, CXCL10 mutants showed less severe lung injury than those with enhanced expression. CXCL10 has been connected to COVID-19 related demyelination, which sustains the cytokine storm and may trigger ARDS, and therefore may be a common denominator between olfactory issues and disease severity.